mid-1

MID-1 is an inhibitor of MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction. It disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake

1. trans-Cinnamaldehyde (Phenylacrolein) exhibits excellent anti-inflammatory activities and antidepressant-like effects in stressed mid-aged rats as a COX-2 inhibitor. 2. Cinnamic aldehyde induces apoptosis of CML cells in vitro, down-regulation of the expression and function of BCR-ABL may be one of its most important anti-leukemia mechanisms. 3. Cinnamic aldehyde and cinnamic acid are cardioprotective in a rat model of ischemic myocardial injury, the mechanism is related to anti-oxidative and anti-inflammatory properties.

1-Palmitoyl-3-stearoyl-rac-glycerol, a diacylglycerol, features palmitic acid at the sn-1 position and stearic acid at the sn-3 position. This compound appears in palm-based diacylglycerols derived from palm stearin, palm mid fraction, palm oil, and palm olein, as well as in extracts of wheat bran and brewer’s spent grain.

Solanezumab, a humanized monoclonal IgG1 antibody targeting the mid-domain of the amyloid-β (Aβ) peptide, shows promise for Alzheimer’s disease research [1].

DBCO-SS-PEG4-Biotin, a cleavable, mid-functional ADC linker with a 4-unit PEG moiety, is used in the synthesis of antibody-drug conjugates (ADCs)[1].

1,3-Distearoyl-2-linoleoyl glycerol, a triacylglycerol, features stearic acid at the sn-1 and sn-3 positions and linoleic acid at the sn-2 position. This compound is present in cocoa butter and in cocoa butter equivalents (CBEs) that include shea stearin and palm mid fraction.

1. Cinnamaldehyde (Cinnamic Aldehyde) has antipyretic activity. 2. Cinnamaldehyde is a sedative agent. 3. Cinnamaldehyde inhibits invasive capabilities of MDA-MB-435S cells was correlated with down-regulating the expression of miR-27a. 4. Cinnamaldehyde induces the generation of reactive oxygen species and exerts vasodilator and anticancer effects. 5. Cinnamaldehyde appears to be a promising candidate as an adjuvant in combination therapy with 5-fluorouracil (5-FU) and oxaliplatin (OXA), two chemotherapeutic agents used in CRC treatment. The possible mechanisms of its action may involve the regulation of drugmetabolizing genes. 6. Cinnamaldehyde plays a certain role in inhibiting the occurrence and progression of melanoma and its action mechanism may be manifested by inhibiting expression of VEGF and HIF-α, thus blood vessel simulation and formation of new blood vessels of melanoma cells, and growth of tumors accordingly.